UK Breast Cancer Consultants

Dr Susan Cleator is a Consultant Clinical Oncologist based at Charing Cross Hospital, part of Imperial College Healthcare NHS Foundation Trust.

Dr Cleator trained at Oxford University and Hospitals, and undertook her oncology training at the Charing Cross, Hammersmith, Mount Vernon and The Royal Marsden Hospitals. During this period she also spent three years working full-time on her PhD project at the Institute of Cancer Research and Royal Marsden Hospital. This focused on identifying a molecular assay for predicting the response of breast cancers to chemotherapy. She has published on this and a number of other aspects of oncology.

She works closely with her surgical colleagues at St Mary's hospital where she is responsible for the chemotherapy and radiotherapy aspects of their treatment, specializing in breast, colorectal and lymphomatous cancers. 

Dr Cleator was previously a member of Breast Cancer Studies Group (overseeing Breast Cancer National Research portfolio) and is a member of the American Association Cancer Physicians and the British Medical Association.

Mr Stuart Wilson is a Consultant in Plastic Surgery based at The University Hospital South Manchester.

Mr Wilson qualified at Sheffield University Medical School and trained in Plastic Surgery in Leeds and Manchester. He undertook a travelling fellowship during 1998 where he spent time in the plastic and hand surgery units at Ljubljana in Slovenia, Zurich, Switzerland and Nancy in France. 

He later underwent subspecialty fellowships training in Manchester for breast and hand surgery. Mr Wilson carries out a wide range of cosmetic procedures at The Alexandra Hospital including abdominal reduction, liposuction, breast enlargement and reduction, rhinoplasty (nasal surgery), face lift and eyelid surgery as well as thigh and arm lift surgery.

Professor Paul Ellis is Professor of Cancer Medicine based at King’s College London and Consultant Medical Oncologist at Guy’s & St Thomas’ Hospital.

Prof Ellis has responsibility for the management of breast cancer.

He studied medicine at Otago University in New Zealand before completing his fellowship in Medical Oncology and postgraduate research degree at the Royal Marsden Hospital in London. He took up his present post in 1997 and has held a number of senior management roles since then including Head of Medical Oncology at Guy’s & St Thomas’, Medical Director for the South East London Cancer Network (SELCN) and Head of Breast Cancer Clinical Research for Guy’s & St Thomas’ and the KCL Division of Cancer Medicine.

He is the author of over 100 peer reviewed scientific papers in the breast cancer field, and has been on the Editorial Board of a number of Oncology Journals including Journal of Clinical Oncology. His major breast cancer research interests include novel clinical research strategies in the adjuvant and neoadjuvant setting with an emphasis on the integration of novel therapies. He was involved in chairing the UK Dept of Health Advisory committee on the introduction of Herceptin into UK clinical practice, and co-authouring the national guidelines on Herceptin use.

Professor Ellis was the principal investigator and co-chair of the trial management group for the UK National Adjuvant Chemotherapy (TACT) Trial and has been involved on the Steering Committees of numerous other clinical trials of novel anti-cancer therapies including being Co-PI on the MARIANNE and KAMILLA trials. He continues to take an active leadership role within the UK and European Clinical Trials community.

Over the last 5 years he has been actively involved in the development and growth of the Sarah Cannon Research Centre in London. He has taken a leadership role in the breast programme and links closely with Sarah Cannon in Nashville and the other centres in the US.

Dr Mark Harries is a Consultant Medical Oncologist based at Guy’s & St Thomas’ Hospitals NHS Foundation Trust and honorary senior lecturer at Kings College London School of Medicine.

Dr Harries specialises in the treatment of Breast Cancer and Melanoma.

Mark graduated from Cambridge University and underwent clinical training at The Royal London Hospital. He trained in Medical Oncology at the Royal Marsden Hospital and completed a PhD and post-doctoral work in the Department of Immunology at University College London.

Dr Harries is a member of the Association of Cancer Physicians, Royal College of Physicians, American Society of Clinical Oncology, European Society of Medical Oncology and the British Medical Association.

Dr Lucy Brazil is a Consultant Clinical Oncologist based at Guy's and St Thomas' NHS Foundation Trust.

Dr Brazl has a special interest in neuro-oncology, in particular, the treatment of glioblastoma multiforme and low grade glioma (including oligodendroglioma). She trained in oncology at Royal Marsden Hospital and Guy's and St Thomas’ Hospitals. She was awarded an MD in 2007 for research into breast cancer genetics at the Institue of Cancer Research and Breakthrough Breast Cancer. 

Dr Brazil is an active member of The National Cancer Institute Brain Tumour Clinical Studies Group, as well as The European Organisation for Research and Treatment of Cancer Brain Tumour Group. She is also Chairman of The Brain Tumour Palliative Care / Quality of Life subgroup.

Dr Brazil was Chief investigator for the CODEL brain tumour study using chemotherapy and radiotherapy for Gliomas,

Chairman of the brain tumour Palliative care QOL sub-group, and Systemic Chemotherapy Neuro-oncology Research lead at Guy’s and St Thomas’.

Professor Justin Stebbing is a Consultant Medical Oncologist based at Imperial College Healthcare NHS Trust in London.

Professor Stebbing trained in medicine at Trinity College Oxford, where he gained a triple first class degree. After completion of junior doctor posts in Oxford, he undertook a residency at The Johns Hopkins Hospital in the US, returning to London to continue his training in oncology at The Royal Marsden and St Bartholomew’s Hospitals. Professor Stebbing’s PhD research investigated the interplay between the immune system and cancer.

Professor Stebbing has published over 500 peer-reviewed papers in journals such as the Lancet, New England Journal, Blood, the Journal of Clinical Oncology, Annals of Internal Medicine, as well as writing for national newspapers and presenting new data on optimal cancer therapies at major international conferences. His focus is on new therapies in cancer, and the systemic management of patients with a variety of solid malignancies, including a number of new biomarker-based approaches, with an emphasis on circulating tumour cells. His laboratory work is concentrated on new druggable target discovery.

He is a member of the Royal College of Physicians, the American Board of Internal Medicine and the Royal College of Pathologists, and sits on the advisory Boards of five biotechnology companies. He chairs the World Vaccine Congress and is on the editorial board of a number of world leading general medical and cancer journals such as the Journal of Clinical Oncology and Oncogene and writes BMA guidelines for several cancers.

Dr Chris Cottrill is a Consultant Clinical Oncologist based at Barts Cancer Centre (St Bartholomews Hospital) in London.

Dr Cottrill specialises in Breast and Gastrointestinal (oesophagus, stomach, pancreas, colon, rectum and anus) cancers and has a specialist interest in stereotactic radiosurgery (CyberKnife treatment). He has a particular interest in combined modality therapy (combination chemo-radiotherapy). He has been a Consultant at St Bartholomew's Hospital for 10 years and is experienced in all aspects of the chemotherapy and radiotherapy treatment of Breast and Gastrointestinal cancers.

Within the field of radiotherapy Dr Cottrill has a specialist interest in combined chemo-radiotherapy, intensity-modulated radiotherapy (IMRT, RapidArc, VMAT) and image-guided radiotherapy (IGRT). He is fully accredited in the use of CyberKnife stereotactic ablative radiotherapy (SABR) at Barts Hospital, the London Clinic and the Harley Street Clinic CyberKnife units.

Since 2000 Dr Cottrill has lectured annually on international postgraduate courses in the field of evidence-based radiation therapy for the European Society for Radiotherapy and Oncology (ESTRO). 

Professor Andrew Tutt is a consultant clinical oncologist based at the Guy’s Hospital Breast Unit and is a Professor of Oncology at King’s College London School of Medicine.

Prof Tutt trained in clinical oncology at the Royal Marsden Hospital London and in breast cancer research at London’s Institute of Cancer Research, where he gained his PhD in Cancer Biology.

Professor Tutt focuses his clinical practice exclusively on breast oncology and its biological, chemotherapy and radiation therapies. He has a particular research interest in “triple negative” and BRCA1 and BRCA2 associated breast cancers where he has led a number of international clinical trials of drug therapies and is the director of a research program focusing on these areas.

Professor Tutt has published and presented a large number of breast cancer research papers and is an invited speaker and session chair at major European and North American Cancer Medicine conferences. He is a member of the St Gallen International Breast Cancer Consensus Panel that develops international breast cancer treatment guidelines and a member of a UK team testing new techniques in breast radiotherapy.

Professor Tutt offers a range of systemic therapy treatments recommended by international guidelines at LOC at London Bridge Hospital and LOC at 95 Harley Street and the radiotherapy at the Harley Street Clinic Cancer Centre and at the Clinical Oncology departments in the Integrated Cancer Centre at Guy’s and St Thomas’s Hospitals near London Bridge and Waterloo Stations.

Dr Alison Jones is a Consultant Medical Oncologist based at The Royal Free London NHS Foundation Trust.

Dr Jones graduated from Bristol University in 1980 and specialised in Medical Oncology, training at The Royal Marsden Hospital, after which she took up a consultant post at The Royal Free Hospital in 1993.

She now specialises in breast cancer and works between The Royal Free and University College Hospital, London in a multidisciplinary team with approximately 300 new cases of breast cancer per annum on each site. She is an active participant in clinical trials and has been on the steering committee for a number of trials within the United Kingdom.

She has an interest in all aspects of breast cancer from diagnosis through treatment, and in particular has an interest in young women with breast cancer, pregnancy-associated breast cancer and fertility-related issues. She has undertaken psychosocial research in relation to breast cancer and family relationships.

She also undertakes clinical trials in the private sector at The Sarah Cannon Institute which is associated with LOC in Harley Street.

She has specific interest in:

• Clinical trials
• Breast cancer in young women (fertility preservation, pregnancy etc.)
• Survivorship
• Introduction of new drugs
• Personalised medicine

She continues on the steering committee of the Association of Cancer Physicians UK having been immediate past chair and advises on the introduction of new drugs through the London Cancer Drugs Group. She is a trustee of Breast Cancer Care, the major UK charity advising and supporting women through breast cancer. She is invited to speak at both national and international meetings.

She continues to publish on breast cancer and has over a hundred and forty publications, mainly in peer review journals.

Dr Jones speaks English and French.

Mr Walid Abou Samra is a Consultant Breast Surgeon based at Glan Clwyd Hospital and Cancer Centre in North Wales.

Mr Abou Samra graduated from the University of Pecs, Hungary in 1995 with an MD in Medicine and completed Postgraduate Training in surgery at the same University, qualifying in General Surgery and Breast Surgery FRCS in 2001. 

He undertook a 12 month elective period in Plastic Surgery with prof Jean-Marie Servant in Hospital St Louis, Paris, France which further stimulated a longstanding interest in breast, oncoplastic and aesthetic surgery.

Mr Walid Abou Samra underwent advanced training in plastic and reconstructive surgery and in 2002, completed further training in both aesthetic and breast surgery in Pecs University, Hungary.

In 2006, he moved with his family to Wales where he continues to work as a consultant at Betsi Cadwaladr University Local Health Board's Glan Clwyd Hospital, Bodelwyddan with interests in breast surgery, breast reconstruction and general surgery.

He has specialised interests in breast cancer, aesthetic breast surgery, including reconstructive and aesthetic breast surgery as well as general surgery. Lead clinician for breast cancer in North Wales and an accredited Breast Test Wales Screening Surgeon. He was also responsible for managing a Foundation Programme in Glan Clwyd and the education and training needs of each junior doctor on the programme at the BCULHB central area.